Partnering spotlight: Robust pipeline at Rexahn led by three phase II drugs
Reviewing the Rexahn Pharmaceuticals pipeline is like reading about a team of potential medal winning Olympic athletes. Each compound is an innovative or first in class product in its therapeutic segment. Three drugs are currently in Phase II clinical trials to treat cancers, central nervous system disorders, and sexual dysfunction. Further, IND filings for two Read more »